vs
Idexx Laboratories（IDXX）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
Idexx Laboratories的季度营收约是Reddit, Inc.的1.6倍（$1.1B vs $663.0M），Reddit, Inc.净利率更高（30.8% vs 22.8%，领先8.0%），Reddit, Inc.同比增速更快（69.0% vs 14.3%），Idexx Laboratories自由现金流更多（$326.3M vs $311.0M），过去两年Reddit, Inc.的营收复合增速更高（53.6% vs 6.4%）
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
IDXX vs RDDT — 直观对比
营收规模更大
IDXX
是对方的1.6倍
$663.0M
营收增速更快
RDDT
高出54.7%
14.3%
净利率更高
RDDT
高出8.0%
22.8%
自由现金流更多
IDXX
多$15.3M
$311.0M
两年增速更快
RDDT
近两年复合增速
6.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $663.0M |
| 净利润 | $248.2M | $204.0M |
| 毛利率 | 60.3% | 100.0% |
| 营业利润率 | 28.9% | 0.0% |
| 净利率 | 22.8% | 30.8% |
| 营收同比 | 14.3% | 69.0% |
| 净利润同比 | 14.8% | 680.0% |
| 每股收益（稀释后） | $3.09 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDXXRDDT
| Q1 26 | — | $663.0M | ||
| Q4 25 | $1.1B | $725.6M | ||
| Q3 25 | $1.1B | $584.9M | ||
| Q2 25 | $1.1B | $499.6M | ||
| Q1 25 | $998.4M | $392.4M | ||
| Q4 24 | $954.3M | $427.7M | ||
| Q3 24 | $975.5M | $348.4M | ||
| Q2 24 | $1.0B | $281.2M |
净利润IDXXRDDT
| Q1 26 | — | $204.0M | ||
| Q4 25 | $248.2M | $251.6M | ||
| Q3 25 | $274.6M | $162.7M | ||
| Q2 25 | $294.0M | $89.3M | ||
| Q1 25 | $242.7M | $26.2M | ||
| Q4 24 | $216.1M | $71.0M | ||
| Q3 24 | $232.8M | $29.9M | ||
| Q2 24 | $203.3M | $-10.1M |
毛利率IDXXRDDT
| Q1 26 | — | 100.0% | ||
| Q4 25 | 60.3% | 91.9% | ||
| Q3 25 | 61.8% | 91.0% | ||
| Q2 25 | 62.6% | 90.8% | ||
| Q1 25 | 62.4% | 90.5% | ||
| Q4 24 | 59.8% | 92.6% | ||
| Q3 24 | 61.1% | 90.1% | ||
| Q2 24 | 61.7% | 89.5% |
营业利润率IDXXRDDT
| Q1 26 | — | 0.0% | ||
| Q4 25 | 28.9% | 31.9% | ||
| Q3 25 | 32.1% | 23.7% | ||
| Q2 25 | 33.6% | 13.6% | ||
| Q1 25 | 31.7% | 1.0% | ||
| Q4 24 | 27.4% | 12.4% | ||
| Q3 24 | 31.2% | 2.0% | ||
| Q2 24 | 26.3% | -11.0% |
净利率IDXXRDDT
| Q1 26 | — | 30.8% | ||
| Q4 25 | 22.8% | 34.7% | ||
| Q3 25 | 24.8% | 27.8% | ||
| Q2 25 | 26.5% | 17.9% | ||
| Q1 25 | 24.3% | 6.7% | ||
| Q4 24 | 22.7% | 16.6% | ||
| Q3 24 | 23.9% | 8.6% | ||
| Q2 24 | 20.3% | -3.6% |
每股收益（稀释后）IDXXRDDT
| Q1 26 | — | $1.01 | ||
| Q4 25 | $3.09 | $1.24 | ||
| Q3 25 | $3.40 | $0.80 | ||
| Q2 25 | $3.63 | $0.45 | ||
| Q1 25 | $2.96 | $0.13 | ||
| Q4 24 | $2.62 | $4.76 | ||
| Q3 24 | $2.80 | $0.16 | ||
| Q2 24 | $2.44 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.1M | $1.4B |
| 总债务越低越好 | $450.0M | — |
| 股东权益账面价值 | $1.6B | $3.2B |
| 总资产 | $3.4B | $3.5B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资IDXXRDDT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $180.1M | $953.6M | ||
| Q3 25 | $208.2M | $911.7M | ||
| Q2 25 | $164.6M | $734.1M | ||
| Q1 25 | $164.0M | $635.7M | ||
| Q4 24 | $288.3M | $562.1M | ||
| Q3 24 | $308.6M | $515.9M | ||
| Q2 24 | $401.6M | $468.0M |
总债务IDXXRDDT
| Q1 26 | — | — | ||
| Q4 25 | $450.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $617.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益IDXXRDDT
| Q1 26 | — | $3.2B | ||
| Q4 25 | $1.6B | $2.9B | ||
| Q3 25 | $1.6B | $2.6B | ||
| Q2 25 | $1.5B | $2.4B | ||
| Q1 25 | $1.4B | $2.2B | ||
| Q4 24 | $1.6B | $2.1B | ||
| Q3 24 | $1.6B | $2.0B | ||
| Q2 24 | $1.6B | $1.9B |
总资产IDXXRDDT
| Q1 26 | — | $3.5B | ||
| Q4 25 | $3.4B | $3.2B | ||
| Q3 25 | $3.4B | $2.9B | ||
| Q2 25 | $3.3B | $2.6B | ||
| Q1 25 | $3.2B | $2.4B | ||
| Q4 24 | $3.3B | $2.3B | ||
| Q3 24 | $3.4B | $2.2B | ||
| Q2 24 | $3.4B | $2.1B |
负债/权益比IDXXRDDT
| Q1 26 | — | — | ||
| Q4 25 | 0.28× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.39× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $355.8M | — |
| 自由现金流经营现金流 - 资本支出 | $326.3M | $311.0M |
| 自由现金流率自由现金流/营收 | 29.9% | 46.9% |
| 资本支出强度资本支出/营收 | 2.7% | — |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $1.1B | $868.6M |
8季度趋势，按日历期对齐
经营现金流IDXXRDDT
| Q1 26 | — | — | ||
| Q4 25 | $355.8M | $266.8M | ||
| Q3 25 | $402.3M | $185.2M | ||
| Q2 25 | $185.7M | $111.3M | ||
| Q1 25 | $238.0M | $127.6M | ||
| Q4 24 | $262.0M | $90.0M | ||
| Q3 24 | $220.1M | $71.6M | ||
| Q2 24 | $248.3M | $28.4M |
自由现金流IDXXRDDT
| Q1 26 | — | $311.0M | ||
| Q4 25 | $326.3M | $263.6M | ||
| Q3 25 | $371.2M | $183.1M | ||
| Q2 25 | $151.6M | $110.8M | ||
| Q1 25 | $207.9M | $126.6M | ||
| Q4 24 | $232.8M | $89.2M | ||
| Q3 24 | $192.0M | $70.3M | ||
| Q2 24 | $215.0M | $27.2M |
自由现金流率IDXXRDDT
| Q1 26 | — | 46.9% | ||
| Q4 25 | 29.9% | 36.3% | ||
| Q3 25 | 33.6% | 31.3% | ||
| Q2 25 | 13.7% | 22.2% | ||
| Q1 25 | 20.8% | 32.3% | ||
| Q4 24 | 24.4% | 20.8% | ||
| Q3 24 | 19.7% | 20.2% | ||
| Q2 24 | 21.4% | 9.7% |
资本支出强度IDXXRDDT
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 0.4% | ||
| Q3 25 | 2.8% | 0.4% | ||
| Q2 25 | 3.1% | 0.1% | ||
| Q1 25 | 3.0% | 0.2% | ||
| Q4 24 | 3.1% | 0.2% | ||
| Q3 24 | 2.9% | 0.4% | ||
| Q2 24 | 3.3% | 0.4% |
现金转化率IDXXRDDT
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 1.06× | ||
| Q3 25 | 1.47× | 1.14× | ||
| Q2 25 | 0.63× | 1.25× | ||
| Q1 25 | 0.98× | 4.88× | ||
| Q4 24 | 1.21× | 1.27× | ||
| Q3 24 | 0.95× | 2.40× | ||
| Q2 24 | 1.22× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
RDDT
暂无分部数据
